memory in subjects with mini-mental state examination of 24-26

Abstract

The invention thus pertains to the use of a composition comprising: (a) uridine or uridine phosphate; and (b) docosahexaenoic acid and/or eicosapentaenoic acid, for improving memory and/or the treatment or prevention of impaired memory function, in a subject with a mini-mental state examination of 24-26, wherein said composition is enterally administered to the subject. In the MMSE test, any score of 27 or higher (out of 30) is effectively normal. In the patients with dementia, 20-26 indicates mild dementia, 10-19 moderate dementia, and below 10 severe dementia. It was the present inventors' belief that within the group of 20-26, the memory impairment in the sub-group of 24-26 may even be reversible, as the pathological pathways have just started to develop. In this group of subjects the pathological pathways have just started to develop. Clinical studies show excellent results for this subgroup.

1 .- 7 . (canceled) 
     
     
         8 . An enteral composition comprising:
 a. uridine or uridine phosphate; and   b. docosahexaenoic acid and/or eicosapentaenoic acid.   
     
     
         9 . The composition according to  claim 8 , further comprising phospholipids, choline, vitamin E, vitamin C, selenium, vitamin B12, vitamin B6 and folic acid. 
     
     
         10 . The composition according to  claim 8 , comprising 0.1-2 g uridine, calculated as uridine monophosphate, per daily dosage unit. 
     
     
         11 . The composition according to  claim 8 , comprising 400-5000 mg of the sum of DHA and EPA per daily dosage unit. 
     
     
         12 . The composition according to  claim 10 , comprising 400-5000 mg of the sum of DHA and EPA per daily dosage unit. 
     
     
         13 . The composition according to  claim 8 , comprising 1-50 gram digestible carbohydrates per 100 ml. 
     
     
         14 . The composition according to  claim 8 , comprising 0.5-10 g protein per 100 ml. 
     
     
         15 . The composition according to  claim 8 , comprising 0.2-3 kcal/ml. 
     
     
         16 . The composition according to  claim 8 , comprising 1-50 gram digestible carbohydrates per 100 ml, 0.5-10 g protein per 100 ml, and 0.2-3 kcal/ml. 
     
     
         17 . The composition according to  claim 8 , being a liquid product, having a viscosity between 1 and 100 mPa.s as measured at a shear rate of 100 s −1  at 20° C. 
     
     
         18 . A method for (i) improving delayed recall function and/or (ii) the treatment and/or prevention of an impaired delayed recall function of a subject, comprising enterally administering to the subject a composition comprising:
 a. uridine or uridine phosphate; and   b. docosahexaenoic acid and/or eicosapentaenoic acid.   
     
     
         19 . The method according to  claim 18 , wherein the subject has a mini-mental state examination of 24-26. 
     
     
         20 . The method according to  claim 18 , wherein the composition is enterally administered to the subject at least one time per day for a period of at least 3 weeks. 
     
     
         21 . A method for improving memory and/or treatment or prevention of impaired memory function in a subject with a mini-mental state examination of 24 or 25, comprising enterally administering to the subject a composition comprising:
 a. uridine or uridine phosphate; and   b. docosahexaenoic acid and/or eicosapentaenoic acid.   
     
     
         22 . The method according to  claim 21 , wherein the composition is enterally administered to the subject at least one time per day for a period of at least 3 weeks.